Latest Health News

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Cluey’s Q3 FY25 results reveal a strong 24% surge in new student enrolments and a narrowing underlying EBITDA loss, signaling a pivotal step toward profitability and renewed revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Winsome Resources navigates lithium market headwinds by optimizing capital, progressing the Adina Lithium Project’s regulatory and feasibility milestones, and expanding its strategic footprint with a high-grade cesium-lithium discovery and extended Renard acquisition option.

Novatti Group Limited has achieved a key turnaround milestone by reporting positive cash EBITDA of $100k in Q3 FY25, alongside record quarterly revenue of $13.4 million and improved margins in its core Payments AU/NZ business.

Biome Australia is set to expand its Activated Probiotics range with two new products targeting vaginal health and perinatal care, tapping into a booming women’s health supplements market.

Titomic Limited advances its strategic U.S. footprint with a new Huntsville facility set to open in June 2025, securing major defense collaborations and expanding commercial momentum in additive manufacturing.

Burgundy Diamond Mines reported a pivotal Q1 2025, completing the transition to Point Lake open pit mining while securing US$73 million in diamond sales and advancing mine life extension plans to 2030 and beyond.